#Spain #Madrid #TTX-MC138 #TransCodeTherapeutics #ESMOCongress

TransCode Therapeutics Set to Present at ESMO Congress 2026

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a pioneer in immuno-oncology and RNA-based treatments for advanced cancers, is gearing up to present significant findings from its Phase 1a clinical trial for TTX-MC138 at the prestigious European Society for Medical Oncology (ESMO) Congress 2026. Scheduled from October 23 to 27 in Madrid, Spain, this event will showcase the latest advances in oncology, attracting medical professionals and researchers worldwide.

Clinical Trial Highlights

The presentation will highlight the clinical evaluation of TTX-MC138, which is a first-in-class antagomiR aimed at combating advanced solid tumors. The poster titled "Phase 1a Clinical Trial of TTX-MC138, a First-in-Class AntagomiR against Advanced Solid Tumors" is expected to shed light on the latest updates regarding this innovative therapeutic candidate.

TTX-MC138 is tailored to target miR-10b, a microRNA known for its role in the progression of metastatic diseases. This targeting of miR-10b represents a novel approach in cancer treatment, specifically for tumors that have a propensity to metastasize. The promise shown in early trial results has raised hopes for patients battling advanced cancer types, who often have limited options.

Dr. Zdravka Medarova, Chief Scientific Officer at TransCode, expressed enthusiasm regarding the acceptance of their poster presentation, stating, "We are honored to have this platform to discuss our clinical findings. Sharing TTX-MC138 results at such a prominent conference allows us to connect with the global oncology community, which is essential for the continued development of our therapeutic technologies."

Event Details

• - Event: ESMO Congress 2026
• - Date: October 23, 2026
• - Location: Madrid, Spain
• - Poster Number: 1025P
• - Category: Developmental Therapeutics

The ESMO Congress is renowned for bringing together experts from various sub-disciplines of oncology to discuss cutting-edge research, share experiences, and shape future clinical practices. It serves as a conduit for advancements in cancer treatment and research, making it an ideal venue for TransCode to present TTX-MC138.

About TransCode Therapeutics

TransCode Therapeutics stands at the forefront of cancer treatment innovations, concentrating on high-risk tumors and developing therapies that are not just effective but also uniquely designed to engage the body's immune system. Apart from TTX-MC138, the company possesses a diverse portfolio of other therapeutic candidates, which are in various stages of preclinical and clinical development. Collaboration with Quantum Leap Healthcare Collaborative further enhances the clinical potential of their treatments, especially within the context of the PRE-I-SPY program, a notable initiative to expedite the assessment of novel cancer therapies.

TransCode is committed to improving outcomes for patients with advanced malignancies. Their forward-looking work in immuno-oncology could redefine the therapeutic landscape for metastatic cancer. As the clinical landscape evolves, maintaining a dialogue with the international medical community will play a crucial role in determining the trajectory of these groundbreaking therapeutics.

For more information on TransCode, their pipeline, and ongoing trials, visit TransCode Therapeutics.

Conclusion

The upcoming ESMO Congress represents not only an opportunity for TransCode Therapeutics to discuss their findings on TTX-MC138 but also a chance to engage with global experts, gather insights, and foster partnerships that may enhance future research and treatment avenues for cancer patients worldwide.